Malignant gliomas remain the most devastating childhood and adult tumors of the central nervous system. Although adult and pediatric gliomas are histologically indistinguishable, they differ in location, behavior, and molecular characteristics. This implies that the molecular pathways and pathophysiology of malignant gliomagenesis in these two populations are distinct. Such differences between adult and pediatric gliomas may predict different therapeutic responses. Therefore, accurate genetically engineered models of adult and pediatric gliomas may help understand the biology of these tumors and evaluate therapeutic agents in preclinical studies. It has been proposed that gliomas arise from the subventricular zone in mice during development. Here, we demonstrate that, in adult mice, gliomas may arise not only when injected in the subventricular zone but also when injected in the cortex and cerebellum. Our work demonstrates a versatile and highly reproducible adult mouse model of glioma, which can be easily incorporated into preclinical studies.
Introduction
Malignant gliomas constitute a genetically and histologically heterogeneous group of tumors associated with significant mortality and morbidity [1] . These tumors occur in children; however, they are far more prevalent in adults. In adults, high-grade gliomas are composed of anaplastic astrocytoma (AA), anaplastic oligodendroglioma, and glioblastoma multiforme (GBM). They can also exist as mixed lineage tumors, most commonly as anaplastic oligoastrocytoma [1] . In general, malignant gliomas progress rapidly and are resistant to therapy [2] . The survival rate for GBM is approximately 1 year [2, 3] , 2 years for AA, and 5 years for anaplastic oligodendroglioma [4] . Although the bulk of research in glioma biology relies on valuable tools such as passaged cell lines and xenograft models, there is growing evidence that these conditions do not represent a comprehensive scope of the cellular complexity human gliomas [5] . Brain tumors are diagnosed principally based on histologic characteristics, with less attention paid to the several known molecular alterations that occur commonly in gliomas, possibly contributing to the poor survival of GBM patients. Although the current histological diagnostic criteria provide good prognostic information, they do not inform optimum therapy. Illustrating this point, as standard of care, all patients with the diagnosis of high-grade gliomas are currently treated identically without consideration of the molecular variables that may impact treatment.
During the last two decades, a number of groups have sought to identify molecular subtypes of gliomas, an undertaking that remains a critical challenge for glioma biologists [2, 6] . Genetic alterations found in adult gliomas have generally been divided into two groups. The first group contains genes that are related to growth factors, their receptors, and signal transduction pathways. These include anomalies of platelet-derived growth factor receptors (PDGFR1/2) [7] [8] [9] [10] , epidermal growth factor receptor [6, 11, 12] , fibroblast growth factor receptor [13, 14] , ciliary neurotrophic factor [15] , and hepatocyte growth factor/scatter factor [16] . The second group encompasses genes implicated in cell cycle regulation, such as the INK4a-ARF locus, which is altered in 60% of GBM [17] , and the RB gene, which is altered in 33% of GBM [18] . Mutations in tumor suppressors TP53 and PTEN are also common genetic alterations in human GBM [19] . In addition to the classification based on basic molecular alterations, GBM can be further subdivided into primary GBM, which arise de novo, and secondary glioblastomas that progress from lower-grade gliomas and likely constitute a highly heterogeneous group [2] .
Our increased understanding of the diverse alterations in human gliomas and the potential significance of these alterations to therapeutic responses have increased the need for additional genetically engineered mouse models. Data obtained from preclinical evaluations of therapies using new genetically engineered mouse models that reflect the heterogeneity of human disease may open new treatment avenues. Furthermore, such studies may help to identify differences in response to therapeutic agents between the various subgroups of glioma and to facilitate the design of individualized therapeutic approaches based not only on histological characteristics but also on genetic alterations and tumor location.
To study glioma development, we have modeled gliomas using the RCAS/tv-a system to initiate tumors in newborn mice with known glioma oncogenic drivers. This model system allows somatic gene transfer of selected oncogenes, such as PDGF and Kras, into targeted brain cells engineered to express the tv-a receptor. These transgenic tv-a mice can then be crossed onto various genetic backgrounds to model the effects of genetic aberrations such as tumor suppressor loss on glioma formation and response to therapy. Using this model, we have observed that oncogenes such as Kras and PDGF produce gliomas with higher grade and shorter latency in mice with Ink4a-Arf−/− and PTEN loss backgrounds (mostly GBM) compared with wild type mice, which develop mostly low-grade tumors [20, 21] . These studies provide important mechanistic insights into the role of specific tumor suppressor loss in PDGF-and Kras-induced pediatric gliomas. The short latency of high-grade glioma development in these tumor suppressor-loss backgrounds, results in animals injected while pups developing GBM when they are very small (∼10-15 g). This feature of our pediatric RCAS/tv-a glioma model presents a challenge for use of these animals in long-term treatment experiments. Because of this limitation and the documented molecular differences between adult and pediatric gliomas [22] [23] [24] , we sought to develop an adult glioma model using RCAS/tv-a methodology. The availability of valid adult glioma models that more easily permit preclinical therapeutic studies are urgently needed and, furthermore, will facilitate comparison of differences in the biology and therapeutic responses between adult and pediatric gliomas.
To generate gliomas in adult mice, we stereotactically delivered PDGFB into adult tv-a mice at various intracranial locations. We were able to generate gliomas by overexpressing oncogenes in nestinand GFAP-positive cells of mice deleted for various tumor suppressors. These mice represent excellent tools for dissecting the role of location, genetic background, and cell of origin in the response to radiation and chemotherapy in adult gliomas. Data obtained from these studies can then be evaluated in parallel with data obtained from pediatric preclinical studies.
Using a stereotactic technique to infect cells in different regions of the brain in adult mice, we investigated the effect of location on the tumor initiating ability of a given oncogene. We chose the subventricular zones (SVZ), a region known to maintain central nervous system stem cells into adulthood, the left and right hemispheres, and the cerebellum. Our results demonstrate that PDGF-driven gliomagenesis is possible in the SVZ, cortex, and the cerebellum, suggesting that tumor-initiating cells responding to PDGF in adults may reside in different intracerebral locations.
Materials and Methods

Mice
Ntv-a wt, Gtv-a wt, Gtv-a Ink4a−/−, Gtv-a Arf−/−, Gtv-a p53−/−, Ntv-a p53, Ntv-a Ink4a-Arf−/− LPTEN, Ntv-a Ink4a-Arf−/− Gli-luc, Gtv-a Ink4a-Arf−/− LPTEN mice were used at an age range of 4 to 6 weeks for all experiments. The genetic backgrounds of tv-a mice are FVB/N, C57BL6, BALB/C, and 129. Generation of tv-a, LPTEN, and Ink4a-Arf, p53 alleles has been described [25] [26] [27] [28] .
Cell Culture and Transfections
DF-1 cells were purchased from ATCC (Manassas, VA). Cells were grown at 39°C according to ATCC instructions. Transfections with RCAS-PDGFB-HA, and RCAS-CRE were performed using Fugene 6 transfection kit (no. 11814443001; Roche, Mannheim, Germany) according to manufacturer's protocol.
Intracranial Injections
Injections were performed using stereotactic fixation device (Stoelting, Wood Dale, IL). Mice used for these experiments were adult from 4 to 6.5 weeks old [29, 30] . There was no significant difference in tumor latency or incidence in this age range (data not shown). Mice were anesthetized with intraperitoneal injections of ketamine (0.1 mg/g) and xylazine (0.02 mg/g). One microliter (for single injections or 1:1 mixture for combined injections) of 4 × 10 4 transfected DF-1 cell suspension was delivered using a 30-gauge needle attached to a Hamilton syringe. Locations were determined according to the instructions in the atlas [31] . Two sets of coordinates for SVZ and right hemosphere were used. Coordinates for SVZ injections were bregma 0 mm, Lat (lateral) −0.5 mm (right of midline), and a depth −1.5 mm from the dural surface; bregma 1.7 mm, Lat −0.5 mm, and a depth 2.5 mm. Left and right hemisphere: AP (Anteroposterior) −2 mm posterior to bregma, Lat −0.5 mm (left or right) depth −1 mm from dural surface; bregma 0.5 mm, Lat 2 mm, and a depth 1 mm. Cerebellum: AP −5.5 mm from bregma. Lat −1.5 mm (to the left), depth −1.5 mm from the dural surface. Mice were monitored carefully and sacrificed when they displayed symptoms of tumor development (lethargy, head tilt).
Tissue Processing
Animals used for histological analysis were killed, and brains were removed and fixed in 10% neutral-buffered formalin for 72 hours.
Fixed tissues were then embedded in paraffin. Formalin-fixed, paraffinembedded specimens were serially sectioned and slide-mounted. The sections were deparaffinized in histoclear (Richard-Allan Scientific, Walldorf, Germany) and were passed through graded alcohols before staining with a hematoxylin and eosin (H&E) reagent.
Immunohistochemistry
An automated staining processing (Discovery; Ventana Medical Systems, Inc., Tucson, AZ) was used for immunohistochemical detection. The protocols were established at the Molecular Cytology Core Facility and at the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center. Anti-PCNA antibodies were obtained from Dako (no. MO879; Glostrup, Denmark), anti-Ki67 from Vector (VP-RMO4, Burlingame, CA), and anti-pH3(Ser10) from Upstate (Lake Placid, NY) (06-570) and were used at 1:2000, 1:200, and 1:800 dilutions in 2% BSA in PBS correspondingly.
Bioluminescent Imaging
Mice were anesthetized with 3% isoflurane before retro-orbital injection with 75 mg/kg body weight of luciferin (Xenogen, Hopkinton, MA). One minute after injection of the luciferin, images were acquired for 4 minutes with the IVIS (Xenogen). A photographic image was taken onto which the pseudocolor image representing the spatial distribution of photon count is projected. We defined a circular region of interest between the ears and used it as a standard in all experiments. From this region, photon counts are compared between different mice.
Magnetic Resonance Imaging
All animals were imaged with a custom-made ID 32-mm quadrature birdcage body resonator (Stark Contrast MRI Research, Erlangen, Germany) while anesthetized using 1.5% isoflurane (Terrell, MINRAD, Inc, Bethlehem, PA). All images were acquired on a Bruker USR 4.7T scanner (Bruker Biospin MRI, Inc, Billerica, MA). The mouse head was imaged in the coronal orientation using a T2-weighted fast spin-echo rapid acquisition with relaxation enhancement sequence with repetition time = 3.5 seconds, echo time = 50 milliseconds, rapid acquisition with relaxation enhancement factor of 8, number of acquisitions = 24, field of view = 3 × 2 cm, slice thickness = 0.7 mm, with an in-plane resolution of 117 × 156 mm. Animal breathing was monitored using an animal physiological monitor system (SA Instruments, Stony Brook, NY) [32] .
Statistical Analysis
Kaplan-Meier survival curves have been made using GraphPad Prism 4 (GraphPad Software, San Diego, CA) and analyzed using log-rank (Mantel-Cox) test: *P < .05; **P < .01; ***P < .001; and absence of star, not significant.
Results
RCAS/tv-a System Allows Generation of Adult Gliomas When Injected in the SVZ
The RCAS/tv-a model has been a very useful and productive tool for studying pediatric brain tumors [33] [34] [35] [36] . During the last few years, data from genomic studies have revealed substantial molecular differences between pediatric and adult malignant gliomas. For example, loss of the PTEN gene and amplification epidermal growth factor receptor are uncommon in pediatric malignant gliomas, whereas these changes frequently occur in adults [22] . Differences in genetics can result in diverse responses to therapy in adult and pediatric gliomas. To model adult gliomas in mice, we delivered expression of the PDGFB gene into the SVZ, where nestin-and GFAP-positive progenitor cells reside in normal brain [37] . Mechanically, we stereotactically injected vectorinfected chicken fibroblasts (DF-1) producing RCAS-PDGFB into the SVZ of adult mice from 4-to 6.5-week-old transgenic mice expressing the tv-a receptor on nestin-positive cells (Ntv-a mice) . Survival results demonstrated that injection of RCAS-PDGFB alone into the SVZ of Ntv-a mice resulted in long latency to tumor formation, but when RCAS-PDGFB was introduced into Ntv-a mice with germ line Ink4a-Arf loss, tumor latency was decreased and tumor grade was significantly increased ( Figure 1A ). Approximately 16% of Ntv-a mice injected with RCAS-PDGFB into the SVZ developed tumors with low-grade histologic finding, whereas when RCAS-PDGF was injected into the SVZ of Ntv-a Ink4a-Arf−/− mice, tumor incidence was 100% and most tumors displayed microvascular proliferation and pseudopalisading necrosis, histologic characteristics of human GBM (Figure 1 , B and C). Tumors generated when injected into the SVZ were mainly located adjacent to the lateral ventricles in the frontal lobe with extension into the olfactory bulb. 
Generation of Gliomas in Different Locations
Recent studies from two different groups have suggested that histologically similar tumors located in different brain regions are molecularly distinct, raising the possibility that these tumors might arise from different cells of origin [38] [39] [40] . To model the tumorigenic potential of different locations in the mammalian brain, we injected RCAS-PDGFB DF-1 producer cells in combination with RCASCre (to induce PTEN loss in mice harboring the floxed PTEN transgene) in four different locations in Ntv-a Ink4a-arf−/− LPTEN mice: 1) the SVZ, 2) the right and the 3) left cerebral hemispheres, and 4) the cerebellum. Figure 2A depicts the Kaplan-Meier survival curve of mice injected in these four different locations. Mice injected in either the SVZ or the right or left cerebral hemispheres show similar survival, whereas mice injected in the cerebellum exhibit significantly longer survival compared with the other three locations. In summary, all of the mice injected in the SVZ and the right and left cerebral hemispheres developed tumors, whereas 83% of cerebellum-injected mice developed tumors ( Figure 2B ). Tumors initiated in all four locations were histologically similar and demonstrated features of GBM ( Figure 2C ), including microvascular proliferation and extensive areas of pseudopalisading necrosis ( Figure 2C ). Platelet-derived growth factor receptor injection with/or without PTEN loss (Figures 2, A and C , and W1A) in the SVZ results in tumor formation in the SVZ with extension into the ipsilateral frontal lobe and olfactory bulb, suggesting that these tumors may migrate within the rostral migratory stream in agreement with published literature [30] . In contrast, tumors initiated at the right and left hemispheres produced tumors with diffuse cortical involvement with no extension into the olfactory bulb and no extension into the brainstem or cerebellum. In agreement with human data [41, 42] , tumor formation resulting from cerebellar injections occurred at lower frequency compared with the other locations. Nevertheless, high-grade tumors arose when PDGFB was injected within the cerebellum with or without PTEN loss (Figures 2A and  W1, A and B) . All tumors generated by these methods exhibited similar proliferation rates as determined by immunostaining for PCNA Ki67 and pH3, regardless of location ( Figures 2D and W2) .
Targeting PDGF to GFAP-Expressing SVZ Cells in Gtv-a (GFAP-tv-a) Mice Leads to GBM Formation with Mixed Oligoastrocytoma Histology
Most genetic alterations occurring in human gliomas result in signal transduction abnormalities or disruption of cell cycle control pathways [43] . The CDKN2A locus, which encodes p16
Ink4A and p14 ARF , is deleted in approximately 60% of human GBM [18] , and the incidence of Figure 3A) . Statistical analysis between right and left hemispheres and SVZ shows the slight advantage of the right hemisphere compared with SVZ (*). All the mice without obvious evidence of tumors were killed at 235 days after injection.
p53 mutations is 31% in GBM and 48% in AA [44] . We used Gtv-a transgenic mice (where the tv-a receptor is expressed on GFAP-positive cells) in wt, p53−/−, Arf−/−, and Ink4a-Arf−/− backgrounds to model the effect of cell cycle abnormalities in gliomas growing in different locations. As shown in Figure 3A , mice with tumors that were generated in backgrounds with deletions of p53, Arf, or Ink4a-Arf had significantly shorter latency compared with wt. Approximately 100% of mice injected in Gtv-a p53−/−, Gtv-a Ink4a-Arf−/−, and Gtv-a Arf−/− background develop GBM with oligoastrocytoma histologic finding, whereas only 22% of Gtv-a mice in a wild type background develop gliomas, all of which were low grade ( Figure 3B ). Tumors in Gtv-a p53−/−, Gtv-a Ink4a-Arf−/−, and Gtv-a Arf−/− background are GBM, composed of regions of more oligoastrocytoma and mixed astrocytoma histologies ( Figure 3C ).
Imaging of Tumor Bearing Mice with Gli-luc Bioluminescence and Magnetic Resonance Imaging
We recently reported the generation of a Gli-luc reporter mouse that can be used to noninvasively image Gli activity in vivo. We demonstrated that Gli activity, measured by luciferase bioluminescence (BLI), correlates with tumor grade [45] . To investigate whether Gli activity can also be used to image adult PDGF-induced gliomas, we injected RCAS-PDGFB through the stereotactic technique into the SVZ of Ntv-a Ink4aArf−/− Gli-luc adult mice. Similar to pediatric tumors modeled with the RCAS/tv-a system, we noted increased bioluminescence at the tumor site in stereotactically injected adult mice. Figure 4 , A and B, shows an example of a BLI image of non-tumorand tumor-bearing mice correspondingly; these tumors can also be imaged ex vivo as shown in the top right panel of Figure 4B . BLI imaging of these mice is a useful tool to monitor tumor response to therapy in vivo. To demonstrate shared characteristics between RCAS/ tv-a-generated tumors in adult mice and their human counterparts, we imaged our tumor-bearing mice using magnetic resonance imaging (MRI). Notably, these tumors share many imaging characteristics with human GBM, as depicted by T2-weighted images of normal mouse brain ( Figure 4C ) and a tumor-bearing mouse stereotactically injected in the SVZ ( Figure 4D ). In summary, both MRI and BLI can be used to monitor tumor presence and response to therapy in vivo in preclinical trials.
Discussion
Mouse models of gliomas have been instrumental for investigating the causative factors for this heterogeneous disease. Furthermore, reliable and accurate models are essential in the implementation of preclinical studies to identify and validate new therapeutic strategies. During the last decade, we have used the RCAS/tv-a technology for modeling pediatric brain tumors, including pediatric gliomas. However, these models have limitations, most notably that the small Table showing the number of mice injected and tumor incidence (%) by PDGFB overexpression in different genetic backgrounds of Gtv-a mice. p53, Arf, or Ink4a-Arf loss cooperate with overexpression of PDGFB to induce high-grade gliomas. In contrast, PDGFB injection in Gtv-a wt mice leads to low-grade glioma formation with low incidence. (C) H&E micrographs showing tumors generated in Gtv-a p53−/− or Arf−/− or Ink4a-Arf−/− resemble mixed oligoastrocytoma histologic diagnosis. Scale bars, 74 μm. Statistical analysis reveals *** when Gtv-a/Ink4a-Arf−/−, Gtv-a/p53−/−, and Gtv-a/Arf−/− are compared with Gtv-a wt; Gtv-a/Ink4a-Arf−/− versus Gtv-a/Arf−/− is not significant; Gtv-a/p53−/− versus to Gtv-a/Arf−/− is **; Gtv-a/Ink4a-Arf−/− versus Gtv-a/p53−/− is *. All mice without obvious evidence of tumors were killed at 146 days after injection.
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size of the mice at the time of tumor development poses significant difficulties when performing treatment studies that require long-term survival of the mice. In addition, several recent observations have indicated that childhood malignant gliomas have important biological characteristics that distinguish them from adult malignant gliomas [22] [23] [24] . These factors led us to develop a novel RCAS/tv-a-based model of adult gliomagenesis that could be used in parallel with our preexisting pediatric models. The existence of these two models now allows investigators to simultaneously compare the therapeutic responses of pediatric and adult gliomas in future studies. Our study also attempts to lend insight into the influence of location on tumorigenic potential and tumor progression in an adult mammalian system of gliomagenesis ( Figure W2 ). It is known that anatomic location in human gliomas influences prognosis and treatment options [46, 47] . We demonstrated that RCAS-PDGFB injected into SVZ induced glioma formation in the SVZ and frontal lobe with extension into the olfactory bulb, a very common location for human gliomas [48] . We demonstrated that tumor incidence, latency, and mortality do not differ when tumors are generated in different locations in the cerebral hemispheres, including the SVZ. By contrast, tumors produced by cerebellar PDGFB overexpression are localized to the cerebellum with extension into the brainstem and occurred with lower incidence and with longer latency compared with cerebral hemisphere and SVZ injections.
Targeting nestin-positive or GFAP-positive cells when injected in the SVZ resulted in tumor formation with similar incidence and latency. We further demonstrated that loss of tumor suppressors p53, Arf, or Ink4a-Arf resulted in higher-grade tumors with shorter latency and 100% incidence compared with their wild type counterparts, in which only 22% of mice developed tumors, all of which are low grade. Finally, because the location of injection resulted in characteristic tumor locations in the mice, it is possible that a correlation exists between tumors and their cells of origin in humans as well.
Adult mice bearing tumors generated by stereotactic injections usually develop tumors when their weight range is 22 to 28 g, an ideal weight for treating mice, making these mice excellent tools for preclinical trials. BLI and MRI techniques further complement this technique, allowing noninvasive monitoring of therapeutic responses. This model will allow investigators to interrogate the role of tumor location, genetic background, and cell of origin (depending which cell type we target originally, nestin− or GFAP−) in response to therapy. We hope that data obtained from preclinical studies in these mouse models will contribute to the development of individual targeted therapies and accelerate the introduction of these therapies into human clinical trials for gliomas. 
